U.S. Markets close in 2 hrs 49 mins
  • S&P 500

    4,158.64
    -26.83 (-0.64%)
     
  • Dow 30

    34,022.40
    -178.27 (-0.52%)
     
  • Nasdaq

    13,890.02
    -162.32 (-1.16%)
     
  • Russell 2000

    2,222.74
    -39.93 (-1.76%)
     
  • Crude Oil

    63.37
    +0.24 (+0.38%)
     
  • Gold

    1,771.70
    -8.50 (-0.48%)
     
  • Silver

    25.80
    -0.31 (-1.19%)
     
  • EUR/USD

    1.2042
    +0.0062 (+0.5178%)
     
  • 10-Yr Bond

    1.5890
    +0.0160 (+1.02%)
     
  • Vix

    18.40
    +2.15 (+13.23%)
     
  • GBP/USD

    1.3989
    +0.0149 (+1.0785%)
     
  • USD/JPY

    108.0710
    -0.7120 (-0.6545%)
     
  • BTC-USD

    54,935.30
    -745.45 (-1.34%)
     
  • CMC Crypto 200

    1,236.73
    -62.23 (-4.79%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its financial results for the full year ended Dec. 31, 2020 after market close on Thursday, Feb. 25, 2021.

Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website.

The conference call can be accessed by dialing (855) 453-3834 or +1 (484) 756-4306 (international) and referencing conference ID 9592143 prior to the start of the call. A replay of the call will be available approximately two hours after the completion of the call and will remain available for seven days. To access the replay, please dial (855) 859-2056 or +1 (404) 537-3406 and refer to conference ID 9592143.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using our proprietary RNAi technologies, GalXC™ and GalXC-Plus™, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes in the liver, Dicerna’s GalXC technology has the potential to address conditions that are difficult to treat with other modalities. Dicerna has continued to innovate and is exploring new applications of its RNAi technology beyond specific hepatocytes, targeting additional tissues and enabling new therapeutic applications with GalXC-Plus. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world’s leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. At Dicerna, our mission is to interfere – to silence genes, to fight disease, to restore health. For more information, please visit www.dicerna.com.

GalXC™ and GalXC-Plus™ are trademarks of Dicerna Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005344/en/

Contacts

Media:
Amy Trevvett
+1 617-612-6253
atrevvett@dicerna.com

Investors:
Lauren Stival
+1 617-514-0461
lstival@dicerna.com